Real World Assessment of Clinical Outcome Changes -Including Month of Ramadan- for Dapagliflozin in Management of Type 2 Diabetes Mellitus
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 17 May 2017
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms REWARD
- Sponsors AstraZeneca
- 07 Jun 2017 Biomarkers information updated
- 10 May 2017 Status changed from recruiting to active, no longer recruiting.
- 17 Mar 2017 Planned End Date changed from 1 Feb 2018 to 28 Feb 2018.